Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease

被引：31

作者：

Behrens, GMN ^{[1
]}

Meyer-Olson, D ^{[1
]}

Stoll, M ^{[1
]}

Schmidt, RE ^{[1
]}

机构：

[1] Hannover Med Sch, Dept Clin Immunol, D-3000 Hannover, Germany

来源：

AIDS | 2003年 / 17卷

关键词：

HIV; antiretroviral therapy; coronary heart disease; lipodystrophy;

D O I：

10.1097/00002030-200304001-00018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Metabolic complications and altered fat distribution associated with HIV infection and antiretroviral therapy may lead to accelerated coronary artery disease (CAD). The high prevalence of multiple cardiovascular risk factors in a significant number of HIV patients is a cause for concern in both patients and physicians. Non-invasive strategies to measure subclinical CAD have been inconclusive. Long-term studies are underway to determine cardiac event rates, intervention strategies and consequences for the clinical management of HIV disease. In the present paper, we summarize the most prevalent risk factors in individuals with HIV infection receiving highly active antiretroviral therapy by focusing on the clinical implications of metabolic abnormalities and HIV-related lipodystrophy on CAD. (C) 2003 Lippincott Williams Wilkins.

引用

页码：S149 / S154

页数：6

共 45 条

[1] ASSOCIATION OF INSULIN AND INSULIN PROPEPTIDES WITH AN ATHEROGENIC LIPOPROTEIN PHENOTYPE [J].

BAVENHOLM, P ;

KARPE, F ;

PROUDLER, A ;

TORNVALL, P ;

CROOK, D ;

HAMSTEN, A .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (11) :1481-1488

[2]

Behrens G, 1998, LANCET, V351, P1958, DOI 10.1016/S0140-6736(98)26026-0

[3] Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors [J].

Behrens, G ;

Dejam, A ;

Schmidt, H ;

Balks, HJ ;

Brabant, G ;

Körner, T ;

Stoll, M ;

Schmidt, RE .

AIDS, 1999, 13 (10) :F63-F70

[4] ApoE genotype and protease-inhibitor-associated hyperlipidaemia [J].

Behrens, G ;

Schmidt, HHJ ;

Stoll, M ;

Schmidt, RE .

LANCET, 1999, 354 (9172) :76-76

[5] Lessons from lipodystrophy:: LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophy [J].

Behrens, GMN ;

Lloyd, D ;

Schmidt, HHJ ;

Schmidt, RE ;

Trembath, RC .

AIDS, 2000, 14 (12) :1854-1855

[6] Lipodystrophy syndrome in HIV infection - What is it, what causes it and how can it be managed? [J].

Behrens, GMN ;

Stoll, M ;

Schmidt, RE .

DRUG SAFETY, 2000, 23 (01) :57-76

[7]

BEHRENS GMN, 2002, 9 INT C RETR OPP INF

[8]

BOZZETTE SA, 2002, 9 INT C RETR OPP INF

[9] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].

Carr, A ;

Samaras, K ;

Thorisdottir, A ;

Kaufmann, GR ;

Chisholm, DJ ;

Cooper, DA .

LANCET, 1999, 353 (9170) :2093-2099

[10] A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].

Carr, A ;

Samaras, K ;

Burton, S ;

Law, M ;

Freund, J ;

Chisholm, DJ ;

Cooper, DA .

AIDS, 1998, 12 (07) :F51-F58

← 1 2 3 4 5 →